• GE Healthcare (Waukesha, Wisconsin) said it is introducing four new clinically specialized ultrasound systems. GE's Compact Series is a new line of ultrasound products that places the power and imaging capabilities of a high-performance, 400-pound system into a laptop-size design. The Compact Series builds upon GE's introduction of Vivid i in 2005, a high-performance cardiovascular ultrasound system in a compact design. GE's Compact Series is now expanded to include the new Voluson iand Logiq isystems – each “i” product is designed to bring specialized, console-quality imaging performance and portability to traditional applications. Voluson i is designed for ob/gyn applications, while the Logiq i will serve the general imaging needs of radiology. GE's “e” products focus on expanding ultrasound's reach to new clinical areas. The new Logiq ewas designed with the speed requirements and imaging applications to support real-time clinical decisions in emergency and surgical settings. GE's new Vivid e provides a dedicated cardiac ultrasound imaging solution for the physician office in an easy-to-use design. GE's Voluson i, Logiq e and Vivid e systems are FDA cleared and will become commercially available in the U.S. in June. Logiq i is also FDA cleared with plans for commercial introduction in September.

• Neoprobe (Dublin, Ohio), a diversified developer of oncology and cardiovascular surgical and diagnostic products, said that it has been granted authorization by the FDA to commence patient enrollment in a Phase II multicenter clinical study to evaluate the safety and efficacy of Lymphoseek, a lymphatic tissue targeting agent. Neoprobe said it intends to enroll up to 80 patients at five of the leading cancer treatment centers in the U.S. under the amended Phase II clinical protocol. Lymphoseek is intended to be used in biopsy procedures for the detection of lymph nodes in breast and melanoma cancer patients.